Approach to immunotherapy for HCC in the liver transplant population
- PMID: 38707244
- PMCID: PMC11068135
- DOI: 10.1097/CLD.0000000000000158
Approach to immunotherapy for HCC in the liver transplant population
Conflict of interest statement
Mario Strazzabosco consults for Engitix. The remaining authors have no conflicts to report.
Figures



References
-
- Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. . Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–1905. - PubMed
-
- Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. . Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1:EVIDoa2100070. - PubMed
-
- Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, et al. . Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): A randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1835–1847. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources